Gossamer Bio, INC 10-Q quarterly reports

Gossamer Bio announced the reacquisition of global rights to seralutinib from Chiesi, alongside a significant debt restructuring and a substantial net loss for the quarter.

Gossamer Bio reported a significant increase in net loss for the nine months ended September 30, 2025, despite progress in its seralutinib clinical programs and ongoing collaboration revenue.

Gossamer Bio, a late-stage biopharmaceutical company, reported a significant net loss and increased cash burn in Q2 2025, driven by higher research and development expenses for its lead candidate seralutinib.

Gossamer Bio reports a net loss of $36.6 million for Q1 2025, with revenue driven by the Chiesi collaboration and ongoing development of Seralutinib.

Gossamer Bio's third quarter 2024 results show a net loss of $30.8 million, but also include significant revenue from a collaboration agreement.

Gossamer Bio announced a profitable second quarter of 2024, driven by a significant collaboration agreement with Chiesi, while also detailing ongoing clinical development and financial updates.

Gossamer Bio reports a net loss of $41.9 million for the first quarter of 2024, while highlighting a new global collaboration with Chiesi for seralutinib.